Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지

Effects of Administration of Oxytocin Antagonist on Implantation and Pregnancy Rates in Patients with Repeated Failure of IVF/ICSI Treatment

체외수정시술의 반복적인 실패 환자에서 옥시토신 길항제 주입이 착상 및 임신에 미치는 영향

  • Ahn, Jun-Woo (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Chung-Hoon (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, So-Ra (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jeon, Gyun-Ho (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Sung-Hoon (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Chae, Hee-Dong (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kang, Byung-Moon (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center)
  • 안준우 (울산대학교 의과대학 서울아산병원 산부인과) ;
  • 김정훈 (울산대학교 의과대학 서울아산병원 산부인과) ;
  • 김소라 (울산대학교 의과대학 서울아산병원 산부인과) ;
  • 전균호 (울산대학교 의과대학 서울아산병원 산부인과) ;
  • 김성훈 (울산대학교 의과대학 서울아산병원 산부인과) ;
  • 채희동 (울산대학교 의과대학 서울아산병원 산부인과) ;
  • 강병문 (울산대학교 의과대학 서울아산병원 산부인과)
  • Published : 2009.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study was performed to evaluate the effect of oxytocin antagonist on the outcome of IVF/ICSI cycles in infertile patients with repeated failure of IVF/ICSI treatment. Method: Forty patients who had experienced two or more failures of IVF/ICSI treatment without low ovarian reserve, were recruited for this prospective randomized study. All patients received controlled ovarian stimulation (COS) using GnRH antagonist multidose protocol (MDP). For the intervention group, intravenous administration of atosiban (mixed vasopressin $V_{1A}$/oxytocin antagonist) started with a bolus dose 6.75 mg one hour before embryo transfer (ET) and continued at an infusion rate of 18 mg/hour. After ET, administered atosiban was reduced to 6 mg/hour and continued for 2 hours. The main efficacy endpoints were clinical pregnancy rate and implantation rate. Results: Patients' characteristics were comparable in the intervention and control groups. COS parameters and IVF results were also similar. The number of uterine contractions for 3 minutes measured just before ET was significantly lower in the intervention group than control group ($3.5{\pm}1.4$ vs $8.7{\pm}2.2$, p<0.001). While there was no statistically significant difference in the clinical pregnancy rate between control group and intervention group (20.0% and 40.0%, p=0.168), the implantation rate was significantly higher in the intervention group, with 16.9% (11/65) compared with 6.0% (4/67) in the control group (p=0.047). There were no differences in ectopic pregnancy rate and miscarriage rate between the two groups. Conclusion: This study demonstrates that administration of oxytocin antagonist during ET can improve the implantation rate probably by decreasing the frequency of uterine contractions in infertile patients undergoing IVF/ICSI treatment.

목 적: 본 연구는 반복적으로 체외수정시술/난자세포질내 정자주입술을 실패했던 환자에서 배아 이식시 옥시토신 길항제의 투여가 임신율 및 착상율에 미치는 영향을 알아보고자 하였다. 연구방법: 2회 이상의 체외수정시술/난자세포질내 정자주입술을 실패했던 40명의 환자들을 대상으로 전향적 무작위 연구를 진행하였다. 과배란유도 방법으로 생식샘자극호르몬분비호르몬 길항제 다회투여법이 사용되었다. 실험군에서는 옥시토신 길항제로 atosiban (vasopressin $V_{1A}$/oxytocin antagonist)을 배아 이식 한 시간 전에 atosiban 6.25 mg을 일회 정주한 뒤, 18 mg/hour의 속도로 지속적 정맥 주입하였다. 배아 이식이 끝난 뒤 atosiban을 6 mg/hour로 감속하여 2시간 동안 추가로 정맥 주입하였다. 실험군과 대조군간의 체외수정시술 결과를 비교 분석하였다. 결 과: 실험군과 대조군간의 평균 나이, 불임 기간 및 체질량 지수와 기저 혈중 난포자극호르몬 및 에스트라디올 농도, 기저 난포강 난포의 수에 통계적으로 유의한 차이는 없었다. 또한 투여된 재조합 인간 난포자극호르몬 (rhFSH)의 총 용량과 투여 기간, 발달된 난포의 개수 및 자궁내막의 두께 역시 통계학적 유의한 차이를 보이지 않았다. 수집된 난자 및 성숙 난자의 수와 수정된 난자와 1등급 혹은 2등급의 배아 및 이식된 배아의 수에도 두 군간의 통계학적으로 유의한 차이를 보이지 않았다. 착상율을 비교하였을 때 실험군은 16.9% (11/65), 대조군은 6.0% (4/67)로 나타났고, p=0.047로 두군 간에 통계학적으로 유의한 차이를 보였다. 임상적 임신율의 경우 실험군은 40.0%로 대조군의 20.0%에 비해 높게 나타나으나 통계학적 유의성엔 도달하지 못하였다. 또한 자궁외 임신 및 유산율에 있어서는 두 군 간에 유의한 차이를 보이지 않았다. 결 론: 체외수정시술/난자세포질내 정자주입술을 시행 받는 환자들에서 배아 이식 동안 옥시토신 길항제를 투여하는 것은 자궁의 수축을 감소시켜 착상율을 증가시킬 수 있을 것으로 생각된다.

Keywords

References

  1. Poindexter AN, 3rd, Thompson DJ, Gibbons WE, Findley WE, Dodson MG, Young RL. Residual embryos in failed embryo transfer. Fertil Steril 1986; 46(2): p. 262-7
  2. Knutzen V, Stratton CJ, Sher G, McNamee PI, Huang TT, Soto-Albors C. Mock embryo transfer in early luteal phase, the cycle before in vitro fertilization and embryo transfer: a descriptive study. Fertil Steril 1992; 57(1): p. 156-62 https://doi.org/10.1016/S0015-0282(16)54793-1
  3. Mansour RT, Aboulghar MA, Serour GI, Amin YM. Dummy embryo transfer using methylene blue dye. Hum Reprod 1994; 9(7): p. 1257-9 https://doi.org/10.1093/oxfordjournals.humrep.a138690
  4. Fanchin R, Righini C, Olivennes F, Taylor S, de Ziegler D, Frydman R. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod 1998; 13(7): p. 1968-74 https://doi.org/10.1093/humrep/13.7.1968
  5. Pinheiro OL, Cavagna M, Baruffi RL, Mauri AL, Petersen C, Franco JG, Jr. Administration of beta2-adrenergic agonists during the peri-implantation period does not improve implantation or pregnancy rates in intracytoplasmic sperm injection (ICSI) cycles. J Assist Reprod Genet 2003; 20(12): p.513-6 https://doi.org/10.1023/B:JARG.0000013652.17193.38
  6. Moon HS, Park SH, Lee JO, Kim KS, Joo BS. Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer. Fertil Steril 2004; 82(4): p. 816-20 https://doi.org/10.1016/j.fertnstert.2004.02.140
  7. Fanchin R, Righini C, de Ziegler D, Olivennes F, Ledee N, Frydman R. Effects of vaginal progesterone administration on uterine contractility at the time of embryo transfer. Fertil Steril 2001; 75(6): p. 1136-40 https://doi.org/10.1016/S0015-0282(01)01787-3
  8. Akerlund M. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. Prog Brain Res 2002; 139: p. 359-65 https://doi.org/10.1016/S0079-6123(02)39030-7
  9. Pierzynski P, Reinheimer TM, Kuczynski W. Oxytocin antagonists may improve infertility treatment. Fertil Steril 2007; 88(1): p. 213 e19-22 https://doi.org/10.1016/j.fertnstert.2006.09.017
  10. Pusey J, Kelly WA, Bradshaw JM, Porter DG. Myometrial activity and the distribution of blastocysts in the uterus of the rat: interference by relaxin. Biol Reprod 1980; 23(2): p. 394-7 https://doi.org/10.1095/biolreprod23.2.394
  11. Mansour RT, Aboulghar MA. Optimizing the embryo transfer technique. Hum Reprod 2002; 17(5): p. 1149-53 https://doi.org/10.1093/humrep/17.5.1149
  12. Dorn C, Reinsberg J, Schlebusch H, Prietl G, van der Ven H, Krebs D. Serum oxytocin concentration during embryo transfer procedure. Eur J Obstet Gynecol Reprod Biol 1999; 87(1): p. 77-80 https://doi.org/10.1016/S0301-2115(99)00077-9
  13. Harper MJ, Bennett JP, Rowson LE. A possible explanation for the failure of non-surgical ovum transfers in the cow. Nature 1961; 190: p. 789-90 https://doi.org/10.1038/190789a0
  14. Torre A, Scheffer JB, Schonauer LM, Frydman N, Fanchin R. Mock embryo transfer does not affect uterine contractility. Fertil Steril 2009 https://doi.org/10.1016/j.fertnstert.2008.10.054